Header Logo

Connection

Philip Bonomi to Aged

Back to Details
This is a "connection" page, showing publications Philip Bonomi has written about Aged.
Philip Bonomi
Connection Strength
1.086
Aged
  1. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9.
    View in: PubMed
    Score: 0.052
  2. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15; 121(6):883-92.
    View in: PubMed
    Score: 0.047
  3. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):338-45.
    View in: PubMed
    Score: 0.042
  4. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.041
  5. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.039
  6. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.037
  7. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009 Jul; 4(7):869-74.
    View in: PubMed
    Score: 0.032
  8. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
    View in: PubMed
    Score: 0.032
  9. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1608-13.
    View in: PubMed
    Score: 0.030
  10. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
    View in: PubMed
    Score: 0.030
  11. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol. 2007 Sep 01; 25(25):3936-44.
    View in: PubMed
    Score: 0.029
  12. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007 May; 2(5):414-22.
    View in: PubMed
    Score: 0.028
  13. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006 Nov 20; 24(33):5253-8.
    View in: PubMed
    Score: 0.027
  14. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
    View in: PubMed
    Score: 0.023
  15. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.017
  16. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 2020 01; 10(1):40-53.
    View in: PubMed
    Score: 0.017
  17. Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer. Ann Surg Oncol. 2019 Nov; 26(12):3807-3808.
    View in: PubMed
    Score: 0.016
  18. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
    View in: PubMed
    Score: 0.016
  19. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):64-72.
    View in: PubMed
    Score: 0.015
  20. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399.
    View in: PubMed
    Score: 0.015
  21. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.015
  22. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer. BMC Cancer. 2017 02 16; 17(1):141.
    View in: PubMed
    Score: 0.014
  23. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
    View in: PubMed
    Score: 0.014
  24. An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
    View in: PubMed
    Score: 0.014
  25. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.013
  26. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.013
  27. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995 Jun; 12(3):199-220.
    View in: PubMed
    Score: 0.012
  28. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.012
  29. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by?Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8.
    View in: PubMed
    Score: 0.012
  30. Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
    View in: PubMed
    Score: 0.012
  31. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.011
  32. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57.
    View in: PubMed
    Score: 0.011
  33. Radiation and simultaneous cisplatin in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993 Oct 20; 27(3):739-46.
    View in: PubMed
    Score: 0.011
  34. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol. 1993 Aug; 16(4):342-5.
    View in: PubMed
    Score: 0.011
  35. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.011
  36. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.010
  37. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. J Thorac Oncol. 2012 Oct; 7(10):1618-21.
    View in: PubMed
    Score: 0.010
  38. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9.
    View in: PubMed
    Score: 0.010
  39. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.009
  40. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.009
  41. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16.
    View in: PubMed
    Score: 0.009
  42. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.009
  43. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.009
  44. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.009
  45. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.009
  46. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Sep; 34(3):357-9.
    View in: PubMed
    Score: 0.008
  47. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.008
  48. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol. 2009 Jun; 32(3):269-73.
    View in: PubMed
    Score: 0.008
  49. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.008
  50. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
    View in: PubMed
    Score: 0.008
  51. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol. 1988 Apr; 15(2 Suppl 1):26-33.
    View in: PubMed
    Score: 0.007
  52. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007 Oct 20; 25(30):4743-50.
    View in: PubMed
    Score: 0.007
  53. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol. 2007 Aug 10; 25(23):3448-55.
    View in: PubMed
    Score: 0.007
  54. Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8.
    View in: PubMed
    Score: 0.007
  55. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006 Nov; 81(2):163-7.
    View in: PubMed
    Score: 0.007
  56. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer. 2006 Jul; 53(1):77-83.
    View in: PubMed
    Score: 0.007
  57. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005 Sep 01; 23(25):5883-91.
    View in: PubMed
    Score: 0.006
  58. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985 Aug; 3(8):1079-85.
    View in: PubMed
    Score: 0.006
  59. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol. 1985 Mar; 12(1 Suppl 1):36-9.
    View in: PubMed
    Score: 0.006
  60. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels. Semin Oncol. 1985 Mar; 12(1 Suppl 1):48-54.
    View in: PubMed
    Score: 0.006
  61. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res. 1985 Feb; 45(2):863-71.
    View in: PubMed
    Score: 0.006
  62. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 01; 23(1):175-83.
    View in: PubMed
    Score: 0.006
  63. MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials. Eur J Cancer. 2004 May; 40(8):1193-8.
    View in: PubMed
    Score: 0.006
  64. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43.
    View in: PubMed
    Score: 0.005
  65. Phase II trial of AMSA in patients with advanced or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Cancer Treat Rep. 1983 Feb; 67(2):197-8.
    View in: PubMed
    Score: 0.005
  66. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer. 2002 Dec; 38 Suppl 8:S13-8.
    View in: PubMed
    Score: 0.005
  67. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95.
    View in: PubMed
    Score: 0.005
  68. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002 Feb 06; 94(3):173-81.
    View in: PubMed
    Score: 0.005
  69. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 2000 Jun; 11(6):673-8.
    View in: PubMed
    Score: 0.004
  70. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg. 2000 May; 66(5):432-6; discussion 436-7.
    View in: PubMed
    Score: 0.004
  71. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5.
    View in: PubMed
    Score: 0.004
  72. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
    View in: PubMed
    Score: 0.004
  73. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999 Apr; 5(4):767-74.
    View in: PubMed
    Score: 0.004
  74. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer. 1998 Jan 15; 82(2):292-300.
    View in: PubMed
    Score: 0.004
  75. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13.
    View in: PubMed
    Score: 0.003
  76. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1995 Jul; 13(7):1615-22.
    View in: PubMed
    Score: 0.003
  77. Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588). Invest New Drugs. 1995; 13(2):137-41.
    View in: PubMed
    Score: 0.003
  78. Combined modality treatment using BID radiation for locally advanced non-small cell lung carcinoma. Cancer. 1994 May 15; 73(10):2599-606.
    View in: PubMed
    Score: 0.003
  79. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1993 May; 11(5):879-84.
    View in: PubMed
    Score: 0.003
  80. Combined modality therapy for locally advanced non-small cell lung carcinoma. Cancer. 1990 Dec 01; 66(11):2270-8.
    View in: PubMed
    Score: 0.002
  81. Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy. Gynecol Oncol. 1990 Sep; 38(3):323-7.
    View in: PubMed
    Score: 0.002
  82. Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):287-92.
    View in: PubMed
    Score: 0.002
  83. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988 Dec; 11(6):630-3.
    View in: PubMed
    Score: 0.002
  84. Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery. 1988 Dec; 104(6):1080-9.
    View in: PubMed
    Score: 0.002
  85. Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):189-95.
    View in: PubMed
    Score: 0.002
  86. Megestrol acetate as primary hormonal therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):34-7.
    View in: PubMed
    Score: 0.002
  87. Sequential hormone therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):38-43.
    View in: PubMed
    Score: 0.002
  88. Hormone receptor studies in axillary metastases from occult breast cancers. Cancer. 1987 Mar 15; 59(6):1170-2.
    View in: PubMed
    Score: 0.002
  89. Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer. Ann Thorac Surg. 1987 Jan; 43(1):87-91.
    View in: PubMed
    Score: 0.002
  90. Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study. Cancer Treat Rep. 1986 Feb; 70(2):293-4.
    View in: PubMed
    Score: 0.002
  91. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4.
    View in: PubMed
    Score: 0.002
  92. Remission of invasive thymoma due to chemotherapy. Two patients treated with cyclophosphamide, doxorubicin, and vincristine. Chest. 1985 Mar; 87(3):377-80.
    View in: PubMed
    Score: 0.002
  93. Qualitative analysis of Coomassie-blue-stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two-dimensional protein electrophoresis. Prostate. 1985; 6(3):315-23.
    View in: PubMed
    Score: 0.001
  94. A ten year experience with hepatic resection. Surg Gynecol Obstet. 1984 Sep; 159(3):223-8.
    View in: PubMed
    Score: 0.001
  95. Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer Treat Rep. 1984 Sep; 68(9):1163-5.
    View in: PubMed
    Score: 0.001
  96. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity. Cancer Chemother Pharmacol. 1982; 9(1):41-4.
    View in: PubMed
    Score: 0.001
  97. Neuroendocrine carcinoma of the cervix: implications for staging and therapy. Gynecol Oncol. 1981 Aug; 12(1):120-8.
    View in: PubMed
    Score: 0.001
  98. Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy. Anticancer Res. 1981; 1(6):335-40.
    View in: PubMed
    Score: 0.001
  99. Treatment of stage D prostatic carcinoma with megestrol acetate. J Surg Oncol. 1981; 17(4):367-71.
    View in: PubMed
    Score: 0.001
  100. Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancer. Cancer Res. 1980 Nov; 40(11):4127-32.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.